Skip to main content
. Author manuscript; available in PMC: 2008 Apr 30.
Published in final edited form as: J Neuroimmunol. 2007 Apr 27;186(1-2):86–93. doi: 10.1016/j.jneuroim.2007.03.014

Figure 2.

Figure 2

SJL mice treated with sPECAM-Fc at symptom onset have improved clinical symptom severity. A. Daily mean clinical score for each group is plotted. Error bars represent the standard error of the mean. p = 0.02, n= 7 PECAM-IgG treated, 6 human IgG-Fc, combined from 2 independent experiments. B. The average percentage of time after onset that mice in each group experienced no clinical symptoms, mild EAE with clinical symptoms greater than zero and less than 2, and severe EAE with clinical symptoms of 2 and above is shown. C. Graphical representation shows the proportion of mice in the group on each day experiencing no onset or no clinical symptoms (white portion of bar), mild EAE (red portion of bar), or severe EAE (black portion of bar).